Antidepressant use in ambulatory cancer patients

Current Oncology Reports

Volumn 8, Issue 4, 2006, Pages 275-281

  Kim, H Florence ^b   Fisch, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CITALOPRAM; CYTOCHROME P450 2D6; CYTOKINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MEDROXYPROGESTERONE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLATINUM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; TAXANE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AMBULATORY CARE; ANOREXIA; ANXIETY DISORDER; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NEUROPATHY; BLEEDING DISORDER; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; BREAST CANCER; CACHEXIA; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COMA; CONVULSION; DELIRIUM; DEPRESSION; DIABETIC NEUROPATHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG POTENTIATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEPATITIS C; HOT FLUSH; HUMAN; HYPERPYREXIA; HYPERREFLEXIA; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; META ANALYSIS; MOOD DISORDER; MUSCLE TWITCH; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRESCRIPTION; PRIAPISM; PSYCHOMOTOR DISORDER; PSYCHOSIS; RESPIRATION DEPRESSION; RESTLESSNESS; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREMOR;

AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; NEOPLASMS;

EID: 33745520020     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0033-5     Document Type: Article

References (56)

1. Baldessarini RJ: Drugs and treatment of psychiatric disorders: antidepressant and antianxiety agents. In The Pharmacologic Basis of Therapeutics, edn 10. Edited by Goodman LS, Hardman JG, Limbird LE, Gilman AG. New York: McGraw-Hill; 2001:485-520.
2. Marangell LB, Yudofsky SC, Silver JM: Psychopharmacology and electroconvulsive therapy. In American Psychiatric Press Textbook of Psychiatry, edn 3. Edited by Hales RE, Yudofsky SC, Talbott JA, Washington DC: American Psychiatric Press Inc.; 1999:1025-1129.
3. Kaufman DW, Kelly JP, Rosenberg L, et al.: Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002, 287:337-344.
4. Harris G: Regulators want antidepressants to list warning. New York Times. March 23, 2004.
5. Passik SD, Dugan W, McDonald MV, et al.: Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998, 16:1594-1600.
6. Naylor CD: The complex world of prescribing behavior. JAMA 2004, 291:104-106.
7. Fisch MJ: Treatment of depression in cancer. J Natl Cancer Inst Monogr 2004, 32:105-111.
8. Williams S, Dale J: The effectiveness of treatment for depression/ depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006, 94:372-390.
9. National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr 2004, 32:9-16.
10. Raison CL, Demetrashvili M, Capuron L, Miller AH: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
11. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
12. Musselman DL, Lawson DH, Gumnick JF, et al.: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
13. Capuron L, Gumnick JF, Musselman DL, et al.: Neurobehavioral effects of interferon alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
14. Cleeland CS, Bennett GJ, Dantzer R, et al.: Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003, 97:2919-2925.
15. Illman J, Corringham R, Robinson D Jr, et al.: Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 2005, 3:37-50.
16. Marx J: Do antidepressants promote tumors? Science 1992, 257:22-23.
17. Miller LG: Antidepressants and cancer: cause for concern? J Clin Psychopharmacol 1993, 13:1-2.
18. Wang PS, Walker AM, Tsuang MT, et al.: Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001, 54:723-734.
19. Weiss SR, McFarland BH, Burkhart GA, et al.: Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin Pharmacol Ther 1998, 63:594-599.
20. Coogan PF, Rosenberg L, Palmer JR, et al.: Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines. Cancer Causes Control 2000, 11:839-845.
21. Dublin S, Rossing MA, Heckbert SR, et al.: Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control 2002, 13:35-45.
22. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, et al.: Psychotropic medication use and risk of hormone-related cancers: The New York University Women's Health Study. J Public Health Med 2000, 22/2:155-160.
23. Cotterchio M, Kreiger N, Darlington G, Steingart A: Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000, 151:951-957.
24. Kreiger N, Cotterchio M, Steingart A, Buchan G: Antidepressant medication use and breast cancer. Am J Epidemiol 2000, 151/11:S27.
25. Harlow BL, Cramer DW, Baron JA, et al.: Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1998, 7:697-702.
26. Fulton-Kehoe D, Rossing MA, Rutter C, et al.: Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 2006, 94:1071-1078.
27. Gonzalez-Perez A, Garcia Rodriguez LA: Breast cancer risk among users of antidepressant medications. Epidemiology 2005, 16:101-105.
28. Chien C, Li CI, Heckbert SR, et al.: Antidepressant use and breast cancer risk. Breast Cancer Res Reat 2005, 95:1-10.
29. Moorman PG, Berchuck A, Calingaert B, et al.: Antidepressant medication use for and risk of ovarian cancer. Obstet Gynecol 2005, 105:725-730.
30. Bahl S, Cotterchio M, Kreiger N: Use of antidepressant medications and the possible association with breast cancer risk. Psychother Psychosom 2003, 72:185-194.
31. Prieto JM, Atala J, Blanch J, et al.: Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. J Clin Oncol 2005, 23:6063-6071.
32. Loprinzi CL, Kugler JW, Sloan JA, et al.: Randomized phase III controlled trial of venlafaxine in the management of hot flashes. Lancet 2000, 356:2059-2063.
33. Loprinzi CL, Sloan JA, Perez EA, et al.: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002, 20:1578-1583.
34. Stearns V, Beebe KL, Iyengar M, et al.: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003, 289:2827-2834.
35. Loprinzi CL, Levitt R, Barton D, et al.: Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006, 24:1409-1414.
36. Jin Y, Desta Z, Stearns V, et al.: CYP2136 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
37. Ashbury FD, Madlensky L, Raich P, et al.: Antidepressant prescribing in community cancer care. Support Care Cancer 2003, 11:278-285.
38. Cleeland CS, Gonin R, Hatfield AK, et al.: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330:592-596.
39. Pharo JA, Zhou L; Pharmacologic management of cancer pain. J Am Osteopath Assoc 2005, 105:21-28.
40. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005, Jul 20; (3): CD005454
41. Goldstein DJ, Lu Y, Detke MJ, et al.: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005, 116:109-118.
42. Stahl SM, Grady MM, Moret C, Briley M: SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spear 2005, 10:732-747.
43. Tasmuth T, Hartel B, Kalso E: Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002, 6:17-24.
44. Shen Y, Connor TJ, Nolan Y, et al.: Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 1999, 65:1773-1786.
45. Yirmiya R: Endotoxin produces a depressive-like episode in rats. Brain Res 1996, 711:163-174.
46. Hinze-Selch D, Schuld A, Kraus T, et al.: Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000, 23:13-19.
47. Morrow GR, Hickok JT, Roscoe JA, et al.: Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003, 21:4635-4641.
48. Cohen MZ, Williams L, Knight P, et al.: Symptom masquerade: understanding the meaning of symptoms. Support Care Cancer 2004, 12(3):184-190.
49. Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005, 352:1112-1120.
50. Asch DA, Parker RM: The Libby Zion case: one step forward or two steps backward? N Engl J Med 1988, 318:771-775.
51. Meijer WE, Heerdink ER, Nolen WA, et al.: Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004, 164:2367-2370.
52. van Walraven C, Mamdani MM, Wells PS, Williams JI: Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001, 323:655-658.
53. Jick JH, Kaye JA, Jick SS: Antidepressants and the risk of suicidal behaviors. JAMA 2004, 292:338-343.
54. Simon G, Savarino J, Operskalski B, et al.: Suicide risk during antidepressant treatment. Am J Psychiatry 2006, 163:41-47.
55. Gibbons RD, Hur K, Bhaumik DK, Mann JJ: The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005, 62:165-172.
56. Isacsson G, Holmgren P, Ahlner J: Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005, 111:286-290.